SteelPeak Wealth’s Coherus Oncology CHRS Stock Holding History

SteelPeak Wealth’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$96.6K	Hold	69,000	–	–	﹤0.01%	623
2026 Q1	$117K	Hold	69,000	–	–	﹤0.01%	553
2025 Q4	$98K	Hold	69,000	–	–	﹤0.01%	522
2025 Q3	$113K	Hold	69,000	–	–	﹤0.01%	555
2025 Q2	$50.5K	Hold	69,000	–	–	﹤0.01%	545
2025 Q1	$55.7K	Hold	69,000	–	–	﹤0.01%	543
2024 Q4	$95.2K	Hold	69,000	–	–	﹤0.01%	517
2024 Q3	$71.8K	Hold	69,000	–	–	﹤0.01%	484
2024 Q2	$119K	Hold	69,000	–	–	0.01%	485
2024 Q1	$165K	Hold	69,000	–	–	0.01%	437
2023 Q4	$230K	Buy	69,000 +15,000	+28%	+$40.2K	0.01%	370
2023 Q3	$202K	Buy	54,000 +12,000	+29%	+$55.4K	0.01%	383
2023 Q2	$179K	Buy	42,000 +21,000	+100%	+$124K	0.01%	396
2023 Q1	$144K	Buy	21,000 +5,000	+31%	+$38.8K	0.01%	360
2022 Q4	$127K	Buy	+16,000	New	+$123K	0.01%	387

Other funds holding CHRS

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

SteelPeak Wealth's CHRS Position: Q2 2026 in Review

SteelPeak Wealth held its Coherus Oncology (CHRS) position steady in Q2 2026 at 69,000 shares worth $96.6K. The position accounts for ﹤0.01% of the portfolio, ranked #623.

SteelPeak Wealth first reported a position in CHRS in Q4 2022 and has held it in 15 quarters since. The position peaked at $230K in Q4 2023. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

SteelPeak Wealth held 69,000 shares of Coherus Oncology worth $96.6K as of Q2 2026.
SteelPeak Wealth left its Coherus Oncology share count unchanged in Q2 2026.
Coherus Oncology made up ﹤0.01% of SteelPeak Wealth's portfolio in Q2 2026, its #623 holding.
SteelPeak Wealth first reported a position in Coherus Oncology in Q4 2022 and has held it in 15 quarters since.
SteelPeak Wealth's Coherus Oncology position peaked at $230K in Q4 2023.
147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on SteelPeak Wealth's 13F filing for Q2 2026, filed 13 Jul 2026.